Cerevel Therapeutics Holdings Inc
(NAS:CERE)
$
41.65
-0.03 (-0.07%)
Market Cap: 7.59 Bil
Enterprise Value: 7.12 Bil
PE Ratio: 0
PB Ratio: 13.44
GF Score: 40/100 - Abbvie Inc To Acquire Cerevel Therapeutics TranscriptDec 07, 2023
- Q3 2023 Cerevel Therapeutics Holdings Inc Earnings Call TranscriptNov 01, 2023$25.35 (+7.19%)Earnings
- Cerevel Therapeutics Holdings Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 12, 2023
- Q2 2023 Cerevel Therapeutics Holdings Inc Earnings Call TranscriptAug 02, 2023$26.33 (-14.09%)Earnings
- Cerevel Therapeutics Holdings Inc at Bank of America Global Healthcare Conference TranscriptMay 10, 2023
- Q1 2023 Cerevel Therapeutics Holdings Inc Earnings Call TranscriptMay 03, 2023$31.92 (+3.32%)Earnings
- Cerevel Therapeutics Holdings Inc at Stifel CNS Days (Virtual) TranscriptMar 29, 2023
- Cerevel Therapeutics Holdings Inc at Cowen Health Care Conference TranscriptMar 06, 2023
- Q4 2022 Cerevel Therapeutics Holdings Inc Earnings Call TranscriptFeb 22, 2023$26.73 (-13.77%)Earnings
- Cerevel Therapeutics Holdings Inc at JPMorgan Healthcare Conference TranscriptJan 10, 2023
- Q3 2022 Cerevel Therapeutics Holdings Inc Earnings Call TranscriptNov 08, 2022$25.7 (-5.20%)Earnings
- Cerevel Therapeutics Holdings Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 12, 2022
- Q2 2022 Cerevel Therapeutics Holdings Inc Earnings Call TranscriptAug 01, 2022$27.66 (+5.21%)Earnings
- Q1 2022 Cerevel Therapeutics Holdings Inc Earnings Call TranscriptMay 10, 2022$22.68 (+2.25%)Earnings
- Cerevel Therapeutics Holdings Inc at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 13, 2021
- Cerevel Therapeutics Holdings Inc at Citi BioPharma Conference (Virtual) TranscriptSep 08, 2021
- Cerevel Therapeutics Holdings Inc R&D Event TranscriptJan 28, 2021
Cerevel Therapeutics Holdings Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 13, 2021 / 02:15PM GMT
Release Date Price:
$34.66
(-5.82%)
Matthew Harrison
Morgan Stanley - Analyst
Great. Good morning, everybody, and thanks for joining us for the next session. I'm Matthew Harrison, one of the biotech analysts here at Morgan Stanley. Very pleased to have Cerevel with us for the next session. Before we get started, I need to read a disclosure statement. Please note that all important disclosures, including personal holdings disclosures and Morgan Stanley disclosures, appear on the Morgan Stanley public website at morganstanley.com/researchdisclosures.
And with that, I'm going to turn it over to Tony Coles, the CEO at Cerevel, to make some opening comments and get us started. Tony, I think you're on mute.
Tony Coles
Cerevel Therapeutics - CEO & Chairperson of the Board of Directors
Thank you.
Matthew Harrison
Morgan Stanley - Analyst
There you go.
Tony Coles
Cerevel Therapeutics - CEO & Chairperson of the Board of Directors
I think that happens automatically with the switchover. Good
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)